Neumentum Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $10M

  • Investors
  • 9

Neumentum General Information

Description

Developer of a pharmaceutical platform intended to offer non-opioid pain therapeutics to patients. The company's platform offers four non-opioid drug candidates in development, from different assets to novel chemical entities, in both hospital and retail markets for acute and chronic pain indications, enabling patients to have options for viable non-opioid analgesics that can effectively treat their moderately severe pain.

Contact Information

Website
www.neumentum.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 350 Springfield Avenue
  • Suite 200
  • Summit, NJ 07901
  • United States
+1 (833)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • 350 Springfield Avenue
  • Suite 200
  • Summit, NJ 07901
  • United States
+1 (833)

Neumentum Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neumentum Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A2) 08-Nov-2023 $10M Completed Clinical Trials - Phase 3
4. Later Stage VC (Series A2) 27-Apr-2023 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series A2) 31-May-2021 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series A1) 30-May-2018 $7.31M $13.3M Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 01-Nov-2017 $6M $6M Completed Startup
To view Neumentum’s complete valuation and funding history, request access »

Neumentum Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-2/A
Series A-2/B
Series A1 6,210,333 $0.001000 $1.18 $1.18 1x $1.18 8.33%
Series A 6,000,000 $0.001000 $1 $1 1x $1 8.05%
To view Neumentum’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Neumentum Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a pharmaceutical platform intended to offer non-opioid pain therapeutics to patients. The company's platfor
Drug Discovery
Summit, NJ
6 As of 2025

Bay Harbor Islands, FL
 

Tampa, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neumentum Competitors (4)

One of Neumentum’s 4 competitors is Avenue Therapeutics, a Corporation company based in Bay Harbor Islands, FL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avenue Therapeutics Corporation Bay Harbor Islands, FL
Pacira BioSciences Formerly VC-backed Tampa, FL
Mallinckrodt Pharmaceuticals Formerly PE-Backed Dublin, Ireland
Heron Therapeutics Formerly VC-backed San Diego, CA
To view Neumentum’s complete competitors history, request access »

Neumentum Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 2

    Pending

  • Expiring in next 12 mo

Neumentum Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4136072-A1 Compositions and methods for treating pain and/or inflammation Pending 15-Apr-2020
EP-4136072-A4 Compositions and methods for treating pain and/or inflammation Pending 15-Apr-2020
US-20220008390-A1 Compositions and methods for treating pain and/or inflammation Inactive 15-Apr-2020 A61K31/415

Neumentum Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neumentum Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Thornapple River Capital Venture Capital Minority
Global Equity Ventures Venture Capital Minority
AngelMD Angel Group Minority
Green Park & Golf Ventures Venture Capital Minority
Angel (individual) Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Neumentum FAQs

  • When was Neumentum founded?

    Neumentum was founded in 2017.

  • Where is Neumentum headquartered?

    Neumentum is headquartered in Summit, NJ.

  • What is the size of Neumentum?

    Neumentum has 6 total employees.

  • What industry is Neumentum in?

    Neumentum’s primary industry is Drug Discovery.

  • Is Neumentum a private or public company?

    Neumentum is a Private company.

  • What is the current valuation of Neumentum?

    The current valuation of Neumentum is .

  • What is Neumentum’s current revenue?

    The current revenue for Neumentum is .

  • How much funding has Neumentum raised over time?

    Neumentum has raised $55.6M.

  • Who are Neumentum’s investors?

    Thornapple River Capital, Global Equity Ventures, AngelMD, Green Park & Golf Ventures, and are 5 of 9 investors who have invested in Neumentum.

  • Who are Neumentum’s competitors?

    Avenue Therapeutics, Pacira BioSciences, Mallinckrodt Pharmaceuticals, and Heron Therapeutics are competitors of Neumentum.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »